Investing  in  the future of mental and brain health

INVESTMENT FOCUS

Neurotech & BCI

Digital Health

Precision Neuroscience

Platforms & Novel Therapeutics

Alternative Modalities

Asset-72

PURPOSE

We fund and support founders revolutionizing brain and mental health through innovative neuroscience and frontier technologies. PsyMed founders align healing, responsibility, and profitability.

 

INVESTMENT FOCUS

We invest in frontier technologies transforming the mental and brain illness epidemic into a flourishing future.

2-1

ARTIFICIAL INTELLIGENCE

 Advanced algorithms and machine learning  to analyze vast data to enable early detection, accurate diagnosis, drug development and personalized treatment

Asset-65

NEUROTECH &
HUMAN AUGMENTATION

Direct connection of technical components with the brain and nervous system are addressing mental health disorders and neurological diseases

Asset-64

PRECISION NEUROSCIENCE

Paradigm of clinical care shifting from general approach for large populations to individual-based deep knowledge of clinical and biological characteristics

1186641

NEW MODALITIES

Genetic, RNA, cell, and any novel interventions that transcend conventional small molecules to transform brain health

Untitled-design-5

HOLISTIC MEDICINE

Interconnection of biology, psychology, environment, and lifestyle, aiming to address root causes and promote overall well-being

Untitled-design-2

NEUROMETABOLISM

Bidirectional relationship between metabolic processes and mental health, through diet, exercise, and gut microbiota can impact brain function and psychiatric disorders.

PNC

PSYCHEDELIC MEDICINE
& NEW COMPOUNDS

Psychedelics and other novel compounds to treat brain and mental health conditions

Untitled-design-3

DIGITAL HEALTH & THERAPEUTICS

Applications, wearables, and platforms that help patients treat, prevent, or manage a disease and enable personalized care

INVESTMENTS

 

Screenshot 2025-06-02 at 9.20.59 AM

STEALTH MARKETPLACE

Marketplace for transformational mental health modalities

Screenshot 2025-06-02 at 9.21.06 AM

STEALTH NEUROTECH

Continuous hormone monitoring

Screenshot 2025-05-27 at 11.04.43 AM

STEALTH BIOTECH

RNAi medicines to treat, delay, and prevent neurodegenerative diseases

Screenshot 2025-05-27 at 11.02.05 AM

STEALTH CARE DELIVERY PLATFORM

Integrated solution for cancer-specific behavioral health

Screenshot 2025-05-27 at 11.04.43 AM

STEALTH BIOTECH

Regenerative medicine for Alzheimer's and beyond

Screenshot 2025-05-27 at 11.04.43 AM

STEALTH BIOTECH

Precision biologics for neuroinflammation

PEOPLE

Screen Shot 2024-10-09 at 11.31.26 AM

Matias Serebrinsky

General Partner & Co-Founder

Matias is an investor, founder, and ecosystem builder. He previously led NVIDIA Inception North America, an accelerator for AI startups. Before that, he co-founded CookUnity, a foodtech company with that delivered 23+ million meals last year. Matias is the co-host of Business Trip.

Screen Shot 2024-10-09 at 11.31.56 AM

Greg Kubin

General Partner & Co-Founder

Greg is a community builder, investor, and founder. He is a co-host of Business Trip, a podcast exploring the future of mental health and wellness. Over 20 investments in psychedelic medicine and mental health companies. Co-founded HelloSponsor, a SaaS sponsorship platform (AngelPad '15). Ex-Morgan Stanley, Viacom.

Screen Shot 2024-10-09 at 11.33.12 AM

Caitlin Ner

Director of Operations

Caitlin is an operator and community builder. She is also production lead of Business Trip. She was previously founding team of a seed stage AI startup, led growth & operations at Cerebral, and alternative investing at BlackRock. Caitlin is ex-Harvard in Economics and Computer Science and a MSc Candidate in Applied Neuroscience at Kings College London.

LINKEDIN  |  TWITTER  

Screenshot 2025-05-21 at 6.37.51 AM

Danny Carbonero PhD

Investment Associate

Danny is an investor and engineer. He previously worked at Breakout Ventures. He holds a PhD in Biomedical Engineering from Boston University, where he was an NIH F31 Fellow, with a research focus in computational neuroscience. During his time in BU, he helped lead Nucleate Boston, activating promising academic technologies.

LINKEDIN TWITTER  

1662929239671

Tucker Schwartz

Analyst

Leads AI integration for the fund and supports on investments.  He is the founder of holistic health company Thrive.

Screen Shot 2024-10-09 at 11.43.44 AM

Dina Burkitbayeva MBA/MS

Co-Founder

CEO/Co-founder at Freedom Biosciences, developing next-generation neuropsychiatric therapeutics. Co-founder at PsyMed Ventures.

Tim Gardnr

Tim Gardner PhD

Venture Partner 

Chair of Bioengineering at University of Oregon. Previously a founding member of Neuralink.

Brooks Leitner

Brooks Leitner MD PhD

Venture Partner

CEO of a longevity company. Previously co-founder & CEO of EpiTET Therapeutics. VC experience at Canaan, Foresite, and BrightEdge.

Negin M.

Negin Mohktari MD PhD 

Venture Partner

Biotech investor and oncology researcher. Previously a Partner at Bioluminescence Ventures and Senior Associate at Genoa Ventures.

Screenshot 2025-05-27 at 10.06.42 AM

John Krystal
MD

Advisor

Psychiatry. Professor of Translational Research, Psychiatry, and Neuroscience at Yale University School of Medicine. Chief of Psychiatry at Yale-New Haven Hospital.

Graham P

Graham Pechenik JD

Advisor 

Legal/IP. Patent attorney. JD from NYU and BS in biochemistry & cognitive neuroscience from UCSD.

Screenshot 2025-05-27 at 10.13.46 AM

Alex Amen
PhD

Advisor

Gene and Cell Therapies. Biomedical scientist and Director of Asset Acquisition at BridgeBio. Postdoctoral training in the Doudna lab.

1718214501994

Chrystal Mavros PhD

Advisor

Microbiology. Scientist at Columbia University focused on gene therapy, microbiota-gut-brain studies, next-gen sequencing, and postmortem brain analysis.

CRSOZDLLUGYHWHYEGRUHM1BH3

Jacob Robinson PhD

Advisor

Neurotech. CEO and Co-Founder of Motif Neurotech. Professor of Electrical and Computer Engineering at Rice University.

Asset-78

Building a company that’s elevating brain and mental health or looking to get involved as an investor?

SEND US AN EMAIL

PsyMed-Logo-Final

©2022 PSYMED VENTURES. ALL RIGHTS RESERVED.